REG - Reckitt Benckiser Gp - Directorate change

Reckitt BenckiserAnnouncement

Today 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260305:nRSE3956Va&default-theme=true

RNS Number : 3956V  Reckitt Benckiser Group PLC  05 March 2026

RECKITT BENCKISER GROUP PLC

DIRECTORATE CHANGE

 

Reckitt announces the appointment of

Harry Kirsch and Deepak Nath as Non-Executive Directors and

the resignation of Margherita Della Valle and Mahesh Madhavan

 

Reckitt Benckiser Group plc (the "Company" or "Reckitt") today announces the
appointment of Harry Kirsch, current CFO of Novartis Pharma AG and Deepak
Nath, current CEO of Smith+Nephew plc, to the Board as Non-Executive
Directors, effective 1 April 2026.

 

Harry is currently CFO of Novartis, having joined in 2003 and held a number of
senior finance roles before being promoted to his current role in 2013. He is
retiring in mid-March. Prior to Novartis, Harry spent 12 years at Procter
& Gamble in various finance roles. He was a Non-Executive Director at
GlaxoSmithKline Consumer Healthcare Holdings Ltd between 2015-2018.

 

Harry currently serves as a Non-Executive Director of the Novartis Venture
Fund.

 

Harry will join the Audit Committee from May 2026.

 

Deepak Nath is currently CEO of Smith+Nephew plc having joined in 2022. Prior
to that Deepak held senior roles at Siemens Healthineers, Abbott Laboratories
Inc, Amgen Inc and McKinsey and Co Inc.

 

Deepak is currently a director of MDIC and AdvaMed.

 

Margherita Della Valle and Mahesh Madhavan, Non-Executive Director's, have
informed the Company of their intention to retire from the Board with effect
from 1 April 2026.

 

Commenting on the Board changes, Sir Jeremy Darroch, Chair of the Board said:

 

"I would like to thank Margherita and Mahesh for their valued contributions to
the Board and respective Committee's. We are delighted that Harry and Deepak
will be joining the Reckitt Board, bringing many years of executive leadership
experience of large global businesses and we welcome the value and expertise
both will bring to the Board."

 

The Company confirms that there is no further information to be disclosed
under the requirements of Listing Rule 9.6.13R in relation to the
appointments.

 

 

Contact Details:

 

Catheryn O'Rourke
 
+44 (0) 1753 217 800

General Counsel & Company Secretary

 

Nick
Ashworth
                        +44 (0) 7408 812350

Investor Relations

 

 

About Reckitt:

 

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a
cleaner, healthier world. We believe that access to the highest-quality
hygiene, wellness and nourishment is a right, not a privilege.

 

Reckitt is the company behind some of the world's most recognisable and
trusted consumer brands in hygiene, health and nutrition, including Air Wick,
Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol,
Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and
more.

 

Every day, more than 20 million Reckitt products are bought globally. We
always put consumers and people first, seek out new opportunities, strive for
excellence in all that we do and build shared success with all our partners.
We aim to do the right thing, always.

 

We are a diverse global team of c. 40,000 colleagues. We draw on our
collective energy to meet our ambitions of purpose-led brands, a healthier
planet and a fairer society.  Find out more, or get in touch with us
at www.reckitt.com (http://www.reckitt.com/)

 

* Reckitt is the trading name of the Reckitt Benckiser group of companies

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUMPWUPQGBC



            Copyright 2019 Regulatory News Service, all rights reserved